EP0832216A4 - Facteur 15 de croissance des fibroblastes - Google Patents

Facteur 15 de croissance des fibroblastes

Info

Publication number
EP0832216A4
EP0832216A4 EP95922978A EP95922978A EP0832216A4 EP 0832216 A4 EP0832216 A4 EP 0832216A4 EP 95922978 A EP95922978 A EP 95922978A EP 95922978 A EP95922978 A EP 95922978A EP 0832216 A4 EP0832216 A4 EP 0832216A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
fibroblast growth
fibroblast
factor
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95922978A
Other languages
German (de)
English (en)
Other versions
EP0832216A1 (fr
Inventor
John M Greene
Craig A Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP0832216A1 publication Critical patent/EP0832216A1/fr
Publication of EP0832216A4 publication Critical patent/EP0832216A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
EP95922978A 1995-06-05 1995-06-05 Facteur 15 de croissance des fibroblastes Withdrawn EP0832216A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007156 WO1996039509A1 (fr) 1995-06-05 1995-06-05 Facteur 15 de croissance des fibroblastes

Publications (2)

Publication Number Publication Date
EP0832216A1 EP0832216A1 (fr) 1998-04-01
EP0832216A4 true EP0832216A4 (fr) 1999-06-16

Family

ID=22249254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95922978A Withdrawn EP0832216A4 (fr) 1995-06-05 1995-06-05 Facteur 15 de croissance des fibroblastes

Country Status (5)

Country Link
EP (1) EP0832216A4 (fr)
JP (1) JPH11506919A (fr)
KR (1) KR19990008319A (fr)
CA (1) CA2217301A1 (fr)
WO (1) WO1996039509A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876967A (en) * 1995-05-12 1999-03-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-2 and methods of use
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US6403557B1 (en) 1996-11-27 2002-06-11 Human Genome Sciences, Inc. Fibroblast growth factor-13
CA2249179A1 (fr) * 1996-03-21 1997-09-25 The Johns Hopkins University School Of Medicine Facteur 3 homologue du facteur de croissance des fibroblastes (fhf-3) et procedes d'utilisation
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
AU3924300A (en) * 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007595A1 (fr) * 1985-06-20 1986-12-31 The Salk Institute For Biological Studies Facteur de croissance des fibroblastes
EP0246753A2 (fr) * 1986-04-22 1987-11-25 The Salk Institute For Biological Studies Antagonistes du facteur de croissance des fibroblastes
EP0608546A2 (fr) * 1992-12-22 1994-08-03 Takeda Chemical Industries, Ltd. Facteur d'activation des cellules gliales, anticorps contre celui-ci et leurs utilisations
WO1995024414A1 (fr) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur-10 de croissance du fibroblaste
WO1996035708A1 (fr) * 1995-05-12 1996-11-14 The Johns Hopkins University School Of Medicine Facteur-1 (fhf-1) homologue du facteur de croissance de fibroblastes et procedes d'utilisation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007595A1 (fr) * 1985-06-20 1986-12-31 The Salk Institute For Biological Studies Facteur de croissance des fibroblastes
EP0246753A2 (fr) * 1986-04-22 1987-11-25 The Salk Institute For Biological Studies Antagonistes du facteur de croissance des fibroblastes
EP0608546A2 (fr) * 1992-12-22 1994-08-03 Takeda Chemical Industries, Ltd. Facteur d'activation des cellules gliales, anticorps contre celui-ci et leurs utilisations
WO1995024414A1 (fr) * 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Facteur-10 de croissance du fibroblaste
WO1996035708A1 (fr) * 1995-05-12 1996-11-14 The Johns Hopkins University School Of Medicine Facteur-1 (fhf-1) homologue du facteur de croissance de fibroblastes et procedes d'utilisation
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Exhibit A" *
"T111/00" *
"T339/97" *
COLIGAN ET AL: "Current protocols in immunology.", 1994, JOHN WILEY & SONS, INC. *
DATABASE EMBL - EMEST16 6 November 1994 (1994-11-06), AUFFRAY C. ET AL.: "H. sapiens partial cDNA sequence; clone c-zug03", XP002100270 *
GALZIE ET AL: "Fibroblast growth factors and their receptors.", BIOCHEM. CELL BIOL., vol. 75, 1997, pages 669 - 685, XP002144481, DOI: doi:10.1139/bcb-75-6-669 *
GARGETT ET AL: "Isolation, characterization and long-term culture of human myometrial microvascular endothelial cells", REPRODUCTION, vol. 15, 2000, pages 293 - 301 *
MASON: "The ins and outs of fibroblast growth factors", CELL, vol. 78, 1994, pages 547 - 552, XP023908576, DOI: doi:10.1016/0092-8674(94)90520-7 *
MIYAMOTO ET AL: "Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique property.", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 7, 1993, pages 4251 - 4259, XP002071233 *
See also references of WO9639509A1 *
SMALLWOOD P M ET AL: "FIBROBLAST GROWTH FACTOR (FGF) HOMOLOGOUS FACTORS: NEW MEMBERS OF THE FGF FAMILY IMPLICATED IN NERVOUS SYSTEM DEVELOPMENT", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, September 1996 (1996-09-01), pages 9850 - 9857, XP002058996 *

Also Published As

Publication number Publication date
WO1996039509A1 (fr) 1996-12-12
AU2767495A (en) 1996-12-24
AU711647B2 (en) 1999-10-21
EP0832216A1 (fr) 1998-04-01
JPH11506919A (ja) 1999-06-22
CA2217301A1 (fr) 1996-12-12
KR19990008319A (ko) 1999-01-25

Similar Documents

Publication Publication Date Title
NO982991L (no) Veksthormon-sekretagoguer
FI963475A7 (fi) Fibroblastin kasvutekijä 10
EP0871705A4 (fr) Facteur de croissance humain du type ccn
EP0725796A4 (fr) Facteur 10 de la differentiation de croissance
EP0717633A4 (fr) Facteur 7 de differenciation de la croissance
DE59509539D1 (de) Zwischenwirbel-implantat
FR2729291B1 (fr) Implant rachidien
DE59605821D1 (de) l/4-SCALLABSORBER
DE69622773D1 (de) Hüftpfanne
EP1062319A4 (fr) Facteur de croissance endothelial vasculaire 2
FR2735198B1 (fr) Piece d'accastillage de type manille-cosse
DE59610160D1 (de) Verstellring
DK0724826T3 (da) Urtepotte
DE69605683D1 (de) Lebensmitteldressing
EP0833904A4 (fr) Facteur de croissance des fibroblastes 14
EP0832215A4 (fr) Facteur 11 de croissance des fibroblastes
FI954252A7 (fi) Luukasvutekijä
FR2727855B1 (fr) Implants d'extension caverneuse
IL112924A0 (en) Easel
EP0832216A4 (fr) Facteur 15 de croissance des fibroblastes
NO960353L (no) 4-aminobenzoylguanidinderivater
FI933949L (fi) Implantat
EP1100887A4 (fr) Facteur 11 de differentiation de croissance
EP0833892A4 (fr) Facteur de croissance de type 2 derive de l'hepatome humain
NO960392L (no) 4-merkaptobenzoylguanidinderivater

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990506

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060407